THE FUNDAMENTALS BEHIND XIENCE ALPINE
The XIENCE Alpine coronary stent system may be used by interventional cardiologists to treat a blockage and open the artery. A stent implant procedure is known as percutaneous coronary intervention.
XIENCE, which is also described as a drug-eluting stent (DES) or more specifically an everolimus-eluting stent (EES), is a leading DES because of its considerable safety data. XIENCE Alpine is engineered for complex intervention.
Precision in Stent Placement
MULTI-LINK design, with 100% accurate mid-marker to mid-marker stent placement, offers precise deployment
True Center Tip
Flexible tip design with co-axial positioning system (CPS) offers peak performance in complex lesions
Higher Performance Catheter
Catheter is engineered to optimize strength, flexibility and pushability
- Zero-transition distal shaft
- Proprietary skive design
- Robust hypotube with optimized thickness
- Specially formulated outer member
Durable Balloon with Flat Compliance
Thin, dual-layer balloon enables high pressure deployment while maintaining flexibility and strength.
UNIQUE DESIGN BEHIND XIENCE SAFETY DATA
All components of the XIENCE Alpine stent are designed for safety.
*10,000,000 implants number is based on data of DES implants through Q1 2017. Comparative claim based on unit usage in U.S., Japan, China, India, top 5 Western Europe, and Korea. Other leading DES: BSX stents (Promus Element, Promus Element Plus, Promus Premier, Synergy); MDT stents (Resolute, Resolute Integrity, Resolute Onyx); Terumo stents (Nobori, Ultimaster); Biotronik stent (Orsiro); and Biosensors stent (BioMatrix). Data on file at Abbott Vascular.
1. Valgimigli M. Effects of cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events: a patient-level meta analysis. EuroPCR 2014.
2. Bangalore S, et al. BMJ. 2013;347:f6625. doi: 10.1136/bmj.f6625.
3. Palmerini T, et al. JACC. 2014;63:299-307. doi: 10.1016/j.jacc.2013.09.061.
4. Colombo A, et al. JACC. 2002;40:1021-1033.
5. Data on file at Abbott Vascular.
6. Kolandaivelu K, et al. Circulation. 2011;123;1400-1409.
7. Kastrati A, et al. Circulation. 2001;103;2816-2821.
8. Perkins LEL, et al. J Interv Cardiol. 2009;22(s1):S28-S40.
9. Otsuka F, et al. JACC Cardiovasc Interv. 2015;8:1248-1260. doi: 10.1016/j.jcin.2015.03.029.
10. Otsuka F, et al. Circ Cardiovasc Interv. 2014;7:330-342.
11. Ding N, et al. J Interv Cardiol. 2009;22(s1):S18-S27.
12. Joner M, et al. J Am Coll Cardiol. 2008;52(5):333-432. doi: 10.1016/j.jacc.2008.04.030.
13. Guidoin R, et al. ASAIO J. 1994;40(3):M870-M879.